Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heterozygous familial hypercholesterolemia (heFH) - Overview
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development
Akeso Inc
Amgen Inc
Beijing Mabworks Biotech Co Ltd
Daewoong Pharmaceutical Co Ltd
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Innovent Biologics Inc
LIB Therapeutics LLC
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma BV
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Junshi Bioscience Co Ltd
Verve Therapeutics Inc
Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles
alirocumab - Drug Profile
Product Description
Mechanism Of Action
bempedoic acid - Drug Profile
Product Description
Mechanism Of Action
ebronucimab - Drug Profile
Product Description
Mechanism Of Action
EPIC-221 - Drug Profile
Product Description
Mechanism Of Action
evicumab - Drug Profile
Product Description
Mechanism Of Action
evolocumab - Drug Profile
Product Description
Mechanism Of Action
gemcabene - Drug Profile
Product Description
Mechanism Of Action
inclisiran - Drug Profile
Product Description
Mechanism Of Action
lerodalcibep - Drug Profile
Product Description
Mechanism Of Action
MIL-86 - Drug Profile
Product Description
Mechanism Of Action
obicetrapib - Drug Profile
Product Description
Mechanism Of Action
ongericimab - Drug Profile
Product Description
Mechanism Of Action
ST-103 - Drug Profile
Product Description
Mechanism Of Action
tafolecimab - Drug Profile
Product Description
Mechanism Of Action
VERVE-101 - Drug Profile
Product Description
Mechanism Of Action
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia
Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years
Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022
Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To 8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations
Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia
Jul 12, 2022: Verve Therapeutics doses first human with an investigatiol in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
May 09, 2022: Verve Therapeutics reports additiol VERVE-101 and Galc-Lipid noparticle Delivery data in non-human primates at TIDES USA 2022
May 02, 2022: Esperion announces publication of CLEAR Harmony open-label extension study data for Bempedoic Acid in the American Jourl of Cardiology
Apr 27, 2022: Amgen announces results from two open label extension studies of Repatha (evolocumab)
Apr 03, 2022: Innovent releases results of a phase 3 clinical study of IBI306 (PCSK-9 inhibitor) in Chinese patients with heterozygous familial hypercholesterolemia at the American College of Cardiology Annual Congress 2022
Feb 08, 2022: Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
Oct 15, 2021: Amgen’s evolocumab receives positive CHMP opinion for the treatment of Heterozygous familial hypercholesterolemia and Familial Hypercholesterolemia
Sep 24, 2021: FDA approves Repatha (evolocumab) in pediatric patients age 10 and older with heterozygous familial hypercholesterolemia
Aug 12, 2021: Innovent’s antibody therapy meets primary goal in Phase III HeFH trial
May 19, 2021: Verve Therapeutics announces ture publication highlighting its use of base editing to potently and durably lower blood PCSK9 and LDL-C in non-human primates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Akeso Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Amgen Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Epicrispr Biotechnologies Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by LIB Therapeutics LLC, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NeuroBo Pharmaceuticals Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NewAmsterdam Pharma BV, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Novartis AG, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Verve Therapeutics Inc, 2022
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, 2022
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, 2022